Molecular Insights into Osteosarcoma

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 1013

Special Issue Editors

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2B7, Canada
Interests: cardiovascular and gastrointestinal diseases; bone and soft tissue sarcomas; public health

Special Issue Information

Dear Colleagues,

The quote “Cellular pathology is not an end if one cannot see any alteration in the cell. Chemistry brings the clarification of living processes nearer than does anatomy. Each anatomical change must have been preceded by a chemical one.” as stated by Rudolf Virchow (Coper, H., Herken, H., 1963. Dtsch. Med. Wochenschr. 88, 2025–2036) is one of the most formidable excerpts of this outstanding pathologist and public health innovator who worked not only within scientific subjects, but also the social sciences in his time and beyond. Osteosarcoma is a comparatively painstaking topic for many paediatricians, paediatric surgeons, and paediatric pathologists, because despite progress in numerous paediatric malignancies, the outcomes of the affected individuals are still quite poor.

We would be very grateful to gather basic science articles and clinical reports for this Special Issue, which concentrates on the molecular insights of osteosarcoma. As Virchow stated, a chemical change is the basis of what the pathologists sees under the microscope and the physician can assess clinically. We hope to receive several contributions that may attract the attention of funders and charities in promoting more research in the relatively poorly explored field of pre-cancerous bone histology.

 

Sincerely,

Dr. Fan Shen
Prof. Dr. Consolato M. Sergi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • osteosarcoma
  • molecular pathology
  • glucose metabolism
  • precancerosis
  • bone pathology
  • outcome

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 3348 KiB  
Article
Potential Cytoprotective and Anti-Apoptotic Effect of Metamizole Alone and in Combination with Cytostatic Drugs Observed In Vitro in Canine (D-17) and Human (U-2 OS) Osteosarcoma Cell Lines
by Dominik Poradowski, Aleksander Chrószcz, Radosław Spychaj and Vedat Onar
Biomedicines 2024, 12(3), 571; https://doi.org/10.3390/biomedicines12030571 - 03 Mar 2024
Viewed by 679
Abstract
Metamizole (dipyrone) is still a frequently used drug in human and veterinary medicine, especially for pain relief, sometimes also in osteosarcoma treatment. It has a very strong analgesic and antipyretic effect and weaker anti-inflammatory activity. Additionally, it has spasmolytic properties. It is used [...] Read more.
Metamizole (dipyrone) is still a frequently used drug in human and veterinary medicine, especially for pain relief, sometimes also in osteosarcoma treatment. It has a very strong analgesic and antipyretic effect and weaker anti-inflammatory activity. Additionally, it has spasmolytic properties. It is used in many species, including dogs, cats, pigs, cattle, horses, and humans, in Europe, Canada, and South America. The aim of this study was to assess a potential synergism of metamizole as a non-steroidal anti-inflammatory drug with routinely used cytostatics (cisplatin, carboplatin, doxorubicin, and etoposide). In vitro studies were performed on a canine osteosarcoma D-17 cell line and a human U-2 OS cell line. We used the MTT method to assess cell viability, TUNEL staining to assess proapoptotic effects, and propidium iodide to analyse the cell cycle (potential arrest). The obtained results showed that metamizole at 50 μg/mL has potential cytoprotective and anti-apoptotic effects. Metamizole administered simultaneously with cytostatic drugs reduced their cytotoxic effect, which may suggest that such a combination of drugs used in the treatment of osteosarcoma may significantly reduce therapy effectiveness. Full article
(This article belongs to the Special Issue Molecular Insights into Osteosarcoma)
Show Figures

Figure 1

Back to TopTop